Clinical characteristics and survival outcomes of patients with pneumonectomies: A population-based study

Abstract

BackgroundPrognostic factors in a pneumonectomy (PN) are not yet fully defined. This study sought to analyze and evaluate long-term survival after pneumonectomies (PNs) for patients with non-small cell lung cancer (NSCLC).MethodsWe obtained data from the Surveillance, Epidemiology, and End Results (SEER) database for patients who underwent PNs between 2004 and 2015. Propensity score matching (PSM) analysis and Kaplan–Meier curves were used to estimate overall survival (OS), while univariate and multivariable Cox proportional hazards regression analyses were applied to create a forest plot.ResultsIn total, 1,376 patients were grouped according to right/left PNs. Before matching, OS was worse after a right PN [hazard ratio (HR): 1.459; 95% CI 1.254–1.697; P < 0.001] and after matching, survival differences between groups were not significant (HR: 1.060; 95% CI 0.906–1.240; P = 0.465). Regression analysis revealed that age, gender, grade, lymph node dissection, N-stage, and chemotherapy were independent predictors of OS (P < 0.05). Chemotherapy was associated with improved OS (P < 0.001).ConclusionsLaterality was not a significant prognostic factor for long-term survival after a PN for NSCLC. Chemotherapy was a significant independent predictor of improved OS. Long-term survival and outcomes analyses should be conducted on larger numbers of patients.

Effect of Chemotherapy in Stage II–IV Large-Cell Lung Carcinoma and Construction of Its Predictive Nomograms: A SEER Analysis

“…The diagnosis of LCLC is more difficult due to the small sample size obtained by transbronchial lung biopsy and the fact that LCLC can only be diagnosed in surgically resected tumors [2,6]. Some previous studies have shown that the prognostic factors affecting lung cancer are mainly the American Joint Committee on Cancer (AJCC) stage, surgery, tumor size, chemotherapy, and level of differentiation [7,8]. Generally, surgery remains the standard of care for stage I lung cancer patients, and stereotactic radiotherapy is the standard for those who cannot undergo surgical resection [9].…”